Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179578 | 1.00 | PABPC1 (0.52) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL18759622 | 0.91 | PABPC1 (0.56) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL28343201 | 0.84 | ACHE (0.45) | PABPC1APOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL28346760 | 0.84 | PABPC1 (0.51) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL28343199 | 0.84 | ACHE (0.45) | PABPC1APOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL28346759 | 0.84 | PABPC1 (0.51) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL4596085 | 0.83 | ALDH1A1 (0.40) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL31274030 | 0.82 | PABPC1 (0.47) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL9796155 | 0.82 | LMNA (0.42) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 | |
| SCHEMBL8467351 | 0.81 | PABPC1 (0.55) | PABPC1APOBEC3AAPOBEC3GALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590552-B | Synthetic method of acetate compound | 青岛农业大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-110590552-A | Synthetic method of acetate compound | 青岛农业大学 | 2019-12-20 | — | — | CN | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| CN-1910144-B | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD | 2010-06-09 | — | — | CN | disclosed |
| CN-100548976-C | The sulfone amide derivative that is used for the treatment of disease | PFIZER LTD (US) | 2009-10-14 | — | — | CN | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| CN-1942432-A | Phenylethanolamine derivatives as beta-2 agonists | PFIZER LTD (US) | 2007-04-04 | — | — | CN | disclosed |
| CN-1934071-A | Carboxamide derivatives useful as adrenergic receptors | PFIZER LTD (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1910144-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | disclosed |
| CN-1910143-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PABPC1 725/4885APOBEC3A 2043/4885APOBEC3G 2324/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PABPC1 725/4885APOBEC3A 2043/4885APOBEC3G 2324/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PABPC1 725/4885APOBEC3A 2043/4885APOBEC3G 2324/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PABPC1 725/4885APOBEC3A 2043/4885APOBEC3G 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.